DSIP / Emideltide
Sleep-wake / withdrawal research peptide; Old human studies, unresolved mechanism
Brief Overview: DSIP stands for delta sleep-inducing peptide. The FDA name used in the 2026 compounding review is Emideltide. It is a nine-amino-acid peptide that became famous because early rabbit experiments suggested it could increase slow-wave, delta-like EEG activity. In modern terms, it should be read as a sleep-wake and neuroendocrine research peptide, not as a proven sleeping pill. Evidence lens: DSIP has more human history than many gray-market peptides, but that history is old, small, and mixed. A few studies explored insomnia, narcolepsy, alcohol withdrawal, and opioid withdrawal. Later reviews emphasize that the natural DSIP system remains poorly characterized: no clearly validated DSIP gene, precursor, receptor, or single mechanism explains all reported effects. How to read this: if you're new, separate the name from the proof. “Sleep-inducing” is a historical label, not a guarantee. Once you're past the basics, focus on three uncertainties: whether the measured DSIP-like material is truly the same peptide, whether exogenous DSIP reaches the relevant brain targets by a given route, and whether the effect is circadian modulation rather than direct sedation.
- DSIP is a synthetic version of a nonapeptide originally isolated from rabbit cerebral venous blood after hypnogenic electrical stimulation.
- The commonly cited sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, abbreviated WAGGDASGE.
- The molecular formula is C35H48N10O15 and the molecular weight is about 848.8 Da.
- The FDA refers to DSIP as Emideltide in the 2026 Pharmacy Compounding Advisory Committee materials.
- The substances being discussed are Emideltide free base and Emideltide acetate.
- In this guide, DSIP, delta sleep-inducing peptide, and Emideltide refer to the same standard nonapeptide unless a modified analog is explicitly named.
- Classification is difficult. It is commonly grouped as a neuropeptide or sleep-wake regulatory peptide.
- It is not a benzodiazepine, non-benzodiazepine hypnotic, orexin antagonist, melatonin agonist, opioid, or approved detoxification medication.
- It belongs in the “old clinical research / unresolved mechanism” category rather than in the “proven prescription sleep drug” category.
- DSIP/emideltide is a sleep-related neuropeptide research compound with unresolved biology, not a reliable sedative. This entry uses the name emideltide, because FDA materials use that term.
- No single DSIP receptor has been validated which is the central scientific limitation.
- Early work treated DSIP as a candidate endogenous sleep factor because of delta-wave EEG findings in animals. Later reviews concluded that the sleep-factor hypothesis is weakly documented and that DSIP-like immunoreactivity may reflect related peptides or fragments rather than one clean endocrine system.
- The most defensible mechanism language is broad: DSIP appears to interact with sleep-wake regulation, stress-axis signaling, neuroendocrine tone, and possibly opioid-related pathways.
- Proposed effects include modulation of ACTH/corticosterone stress responses, interactions with hypothalamic systems, changes in endogenous opioid signaling, and altered neuronal excitability.
- These are mechanistic hypotheses, not confirmed clinical mechanisms.
- DSIP is not a simple sedative. In some narcolepsy research it was reported to reduce daytime sleep attacks and improve alertness, which is the opposite of what a pure hypnotic model would predict.
- A more careful interpretation is that DSIP may influence sleep-wake organization or circadian regulation, but the direction and clinical reliability depend heavily on subject, route, timing, and study design.
- Proposed mechanisms touch sleep regulation, stress axis, pain, and neuroendocrine signaling, but the mechanism is not settled. It does not directly induce delta sleep in a predictable, drug-like way. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Animal discovery and EEG work: The original DSIP concept came from rabbit work showing increased spindle and delta EEG activity after central administration. This supports the historical name but does not prove that peripheral DSIP products reliably improve human sleep.
- Insomnia studies: Small human studies in the 1980s and early 1990s produced mixed results. An open seven-patient study reported improvement after a series of injections, but open studies are vulnerable to expectation and selection bias. A later double-blind study in 16 chronic insomnia patients concluded that short-term DSIP was unlikely to have major therapeutic benefit. Another controlled insomnia study found some sleep-architecture changes, but the clinical significance was limited.
- Narcolepsy research: A small 1984 study reported fewer sleep attacks and better daytime alertness/performance. That finding is scientifically interesting because it suggests possible circadian or state-stabilizing effects, but it is not enough to establish DSIP as a narcolepsy treatment. Modern narcolepsy care is built around well-studied wake-promoting agents, oxybate products, and newer orexin-pathway programs, not DSIP.
- Withdrawal research: Older European studies explored DSIP for alcohol and opiate withdrawal. Reports included IV administration in patients with withdrawal symptoms and later open clinical work in opioid detoxification. These studies are historically relevant and explain why FDA listed opioid withdrawal among the reviewed uses. They are not proof that DSIP can safely replace evidence-based alcohol or opioid withdrawal management.
- Evidence synthesis: The strongest modern editorial position is conservative. DSIP is not pure nonsense, but its evidence base is old, small, heterogeneous, and mechanistically unresolved. Claims that it reliably “maximizes deep sleep,” “resets circadian rhythm,” “treats addiction,” or “fixes cortisol” need to be softened unless tied to a specific study and endpoint.
- Evidence is heterogeneous, older, and mixed. Community sleep reports are relevant to your context, but they are separate from controlled evidence of insomnia treatment. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.
- Protocol 1: Chronic insomnia matched-pairs study [Clinical/Human Trial]; Route: Intravenous; Dose: 25 nmol/kg; Frequency: Before the 3rd, 4th, and 5th study nights; Timing: Before sleep; Duration: 3 treatment nights in study context; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Insomnia sleep-cycle crossover study [Clinical/Human Trial]; Route: Intravenous; Dose: 25 nmol/kg; Frequency: During four nights; Timing: Night/sleep study context; Duration: 4 nights; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Single and repeated injection insomnia reports [Clinical/Human Trial]; Route: Injection; Study used DSIP injections; Dose: 25 nmol/kg body weight; Frequency: Single injections before sleep; Repeated administrations in study reports; Timing: Before sleep; Morning dosing also studied; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 4: CRH/endocrine challenge infusion study [Clinical/Human Trial]; Route: Intravenous infusion; Dose: 3 mg or 4 mg total; Frequency: Single infusion around CRH challenge; Duration: Acute research infusion; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 5: Common clinic/community sleep range [Community/Biohacker/Anecdotal]; Route: Usually subcutaneous; Dose: 100 mcg – 500 mcg; Frequency: Often 2–3 times per week; Timing: 30–60 minutes before sleep; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 6: Community SC evening cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 100 mcg – 500 mcg; Frequency: As needed or nightly in short cycles; Timing: 30–60 minutes before bed; Duration: PRN or 2–4 week cycles; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 7: Biohacker 250 mcg cycle [Community/Biohacker/Anecdotal]; Route: Subcutaneous; Dose: 250 mcg; Frequency: 5 days on / 2 days off; Timing: 1–3 hours before bed; Duration: 8 weeks on / 8 weeks off; Titration/loading: Sensitive users reported starting around 100–150 mcg.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 8: Community nasal spray protocol [Community/Biohacker/Anecdotal]; Route: Intranasal spray; Dose: 100 mcg – 500 mcg per spray; Frequency: 1–2 sprays daily; Timing: Often around 30 minutes before bed; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Community dosing is often evening/night use, but timing, route, and cycling are empirical. There is no basis for promising next-day recovery or sleep-stage correction. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: about 30-40 minutes by the reported 7-8 minute human plasma half-life; About 60-75 minutes if using a 15-minute in-vitro enzymatic degradation estimate.
- Half-life basis: older DSIP literature reports very rapid degradation in plasma/blood, while modern route-specific human PK for common subcutaneous or intranasal products is not established.
- Beginner translation: DSIP clears quickly. A short half-life does not mean it cannot have downstream effects, but it does rule out any long accumulation window.
- Practical interpretation: Steady state is not the best endpoint for DSIP. If an effect exists, it may depend more on timing relative to circadian phase, route, brain access, and downstream signaling than on maintaining a stable blood concentration all day. Route-specific uncertainty matters. IV exposure, subcutaneous absorption, intranasal absorption, and oral exposure are not equivalent. Product salt form, pH, preservatives, degradation, and nasal mucosa condition can all change the amount reaching systemic circulation or the CNS.
- Short peptide exposure may not match sleep architecture outcomes. Without validated human PK/PD, missed-dose or steady-state calculators are not helpful. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Sleep-focused stacks often combine DSIP conceptually with magnesium, glycine, melatonin, GABAergic supplements, Selank, Semax, or “recovery” peptides.
- These combinations are anecdotal. Combining several sedating or neuroactive substances makes it harder to identify which compound caused benefit, next-day impairment, mood changes, or adverse effects.
- Withdrawal-focused combinations are not appropriate for self-experimentation.
- Alcohol, benzodiazepine, and opioid withdrawal can require medical detoxification, monitoring, and evidence-based medications.
- DSIP is not a stand-alone substitute for buprenorphine, methadone, clonidine/lofexidine, benzodiazepine protocols for alcohol withdrawal, or inpatient care when indicated.
- Once you're past the basics, also consider peptide-degradation interactions. The DSIP literature notes degradation by aminopeptidase pathways; Theoretical interactions with peptidase-modifying drugs are not well characterized.
- In practice, DSIP is conceptually separate from a simple supplement stack, and it warrants clinician review when prescription medications are involved.
- Common sleep stacks include magnesium, glycine, melatonin, GABAergic agents, or peptides. Combining with sedatives can increase impairment and makes it harder to know whether sleep quality truly improved. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Human safety information is limited by old and small studies. Reported tolerability in historical studies does not establish long-term safety for modern gray-market products.
- Main practical risks include unknown dose, contamination, endotoxin exposure, nasal irritation if intranasal, injection-site reactions if injectable, headache, unusual dreams, daytime fatigue or paradoxical alertness, mood changes, and sleep disruption.
- Contraindication caution is strongest for pregnancy, breastfeeding, seizure disorders, bipolar disorder or mania history, severe psychiatric instability, untreated sleep apnea, complex sedative use, active substance-use withdrawal, and use alongside alcohol, benzodiazepines, opioids, Z-drugs, barbiturates, phenibut, or other CNS depressants.
- Anyone with opioid or alcohol withdrawal symptoms needs medical care, not an experimental peptide-first plan.
- A quality-control warning belongs here, too. Because DSIP is usually encountered as RUO powder or spray, COA identity, HPLC purity, mass spectrometry, endotoxin testing, sterility where applicable, and lot matching matter.
- A “sleep peptide” label does not prove molecule identity or injection safety.
- Main concerns are next-day grogginess, paradoxical sleep disruption, mood effects, unknown endocrine effects, and interaction with sedatives or alcohol. Quality risk is also relevant because many products are RUO. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- For sleep: track sleep onset latency, wake after sleep onset, total sleep time, awakenings, subjective sleep quality, next-day alertness, and adverse effects. Wearables can be useful for trends but are not polysomnography. A simple sleep diary and Epworth Sleepiness Scale can be more useful than chasing “deep sleep” percentages on a consumer device.
- For suspected sleep disorders: screen for sleep apnea, restless legs, circadian rhythm disorder, medication effects, alcohol use, caffeine timing, and mood disorders before attributing insomnia to a DSIP deficiency. DSIP should not delay proper evaluation of loud snoring, witnessed apneas, morning headaches, dangerous daytime sleepiness, cataplexy, or parasomnias.
- For safety: monitor mood, anxiety, next-day sedation, headaches, blood pressure if symptomatic, injection-site or nasal irritation, and any interaction with sleep medications. For withdrawal contexts, appropriate monitoring is medical: vitals, hydration, withdrawal scales, relapse risk, suicidality, and clinician-directed medication management.
- Track sleep latency, awakenings, total sleep time, next-day function, dreams/nightmares, resting heart rate, and wearable sleep trends cautiously. Wearables are helpful for trend, not definitive sleep staging. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Emideltide free base and Emideltide acetate are scheduled for discussion at the FDA Pharmacy Compounding Advisory Committee meeting on July 24, 2026. The FDA-listed uses being evaluated are opioid withdrawal, chronic insomnia, and narcolepsy. Committee review is not the same thing as FDA approval, and it is not the same thing as immediate legal compounding access. U.S. market status: DSIP/Emideltide is not an FDA-approved drug with a labeled indication. Research-use-only sale does not establish safety, efficacy, sterility, legal prescribing status, or product quality.
- Anti-doping: DSIP is not treated here as an athlete-safe substance. Even if not named specifically, a non-approved peptide marketed for biologic effects can create S0/S2 risk under anti-doping frameworks. Competitive athletes should check the current WADA list and their anti-doping organization before any exposure.
- Emideltide/DSIP is not FDA-approved. PCAC review or nomination history is compounding-list consideration only, not safety validation. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.